Moderna’s Strategic Shift and Financial Outlook Leads to Sell Rating and Lowered Price Target
Leerink Partners analyst Mani Foroohar has reiterated their bearish stance on MRNA stock, giving a Sell rating on November 14.Don't Miss our ...
Heard on the Street Monday Recap: RFK Bridge to Nowhere
Friday was a doozy for many biotech and pharmaceutical companies after news broke late Thursday that President-elect Donald Trump would nominate vaccine skeptic Robert F. Kennedy Jr. to the nation's ...